Bausch + Lomb Vice President & General Manager, U.S. Surgical, Chuck Hess, penned a letter to customers highlighting company announcements from the first quarter, including the commercial launch of the enVista MX60E, the new VICTUS 3.3 software, and the receipt of CE Mark on Stellaris Elite.
The letter also previews some of what’s to come, including clinical trials studying new IOLs and viscoelastics, as well as the launch of a new feature on the Stellaris Elite that aims to streamline the way surgeons plan their surgeries.
March 13, 2018
Dear Eye Care Professional:
We’re extremely proud and excited to have started 2018 strong, already delivering several new products to help enrich your practice today and investing in innovations that will lead us into the future.
The enVista MX60E with StableFlex technology is now available. This next generation hydrophobic acrylic lens provides improved material properties to enhance optic recovery following delivery. With its TruSight optic, enVista remains the first and only single-piece, hydrophobic acrylic IOL domestically available that has been proven to be glistening-free. Additionally, enVista has the potential for increased resistance to scratches and abrasions that may occur during loading and surgical manipulation.
We are now installing all new VICTUS femtosecond Laser systems with our newly FDA approved 3.3 software and retrofitting existing lasers with the new upgrade package as well. Among its advancements, the VICTUS 3.3 software offers a new option for capsulotomy and lens fragmentation centration, as well as automatic pupil centration for the creation of corneal flaps. These features eliminate the need for manual positioning, thus contributing to the precision of the treatment.
Also new for 2018 is the LaserEdge Plus line of disposable knives, which will feature single-handed operation safety guard handles, as well as new blades on many of our most popular LaserEdge designs. The LaserEdge Plus line will also include a selection of disposable LRI knives which represent our latest line extensions.
In January, we received FDA approval of Crystalsert CI-26, as well as the CE Mark from the European Commission on Stellaris Elite, clearing the way for these technologies to be released in the near future.
In the coming months, our investment in innovation will remain strong, with clinical trials studying several new technologies including new IOLs and viscoelastics, as well as the launch of an innovative feature on the Stellaris Elite that will streamline the way surgeons plan their surgeries and enhance their experience with the platform.
We hope you’ll stop by our booth at ASCRS or any of the spring meetings in April to learn more about these and future innovations from Bausch + Lomb. In the meantime, I thank you once again for your continued support and partnership. We love hearing your ideas and feedback, so please reach out to me directly at firstname.lastname@example.org and share your thoughts. If you would like to try the enVista with StableFlex, VICTUS 3.3, our new LaserEdge knife offering or any other technology in our Surgical portfolio, please let me know and I will arrange for that as well.
It’s a privilege and a pleasure to be your trusted healthcare partner working with you towards our shared goal of improving peoples’ lives.
Vice President & General Manager
U.S. Surgical, Bausch + Lomb